Usually, the optimization of the initial antibody candidates is necessary for the development of therapeutic antibodies. The YUMAB platform provides two in-vitro evolution technologies for the optimization of the antibody’s affinity, stability, specificity or selectivity:Additionally, in-silico analysis can be applied to identify and optimize antibodies with the best developability score.
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling
